Cancer therapy due to apoptosis: Galectin-9

International Journal of Molecular Sciences

Volumn 18, Issue 1, 2017, Pages

  Fujita, Koji ^a   Iwama, Hisakazu ^b   Oura, Kyoko ^a   Tadokoro, Tomoko ^a   Samukawa, Eri ^a   Sakamoto, Teppei ^a   Nomura, Takako ^a   Tani, Joji ^a   Yoneyama, Hirohito ^a   Morishita, Asahiro ^a   Himoto, Takashi ^c   Hirashima, Mitsuomi ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c KAGAWA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

Author keywords

Apoptosis; Cancer; Caspase 1; Galectin 9; Glycan; Pyroptosis; Therapy

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BH3 PROTEIN; CASPASE; ECALECTIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; GALECTIN; LGALS9 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER THERAPY; CELL FATE; GENE DELETION; GENE EXPRESSION; GENE LOCATION; GLYCOSYLATION; HUMAN; NONHUMAN; PROTEIN STRUCTURE; REVIEW; X RAY CRYSTALLOGRAPHY; ANIMAL; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; GALECTINS; HUMANS; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 85007579435     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18010074     Document Type: Review

References (104)

1. Kerr, J.F., Wyllie, A.H., Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26, 239–257.
2. Plati, J., Bucur, O., Khosravi-Far, R. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J. Cell. Biochem. 2008, 104, 1124–1149.
3. Steel, G.G., Lamerton, L.F. The growth rate of human tumours. Br. J. Cancer 1966, 20, 74–86.
4. Iversen, O.H. Kinetics of cellular proliferation and cell loss in human carcinomas. A discussion of methods available for in vivo studies. Eur. J. Cancer 1967, 3, 389–394.
5. Refsum, S.B., Berdal, P. Cell loss in malignant tumours in man. Eur. J. Cancer 1967, 3, 235–236.
6. Sharon, N., Lis, H. Lectins as cell recognition molecules. Science 1989, 246, 227–234.
7. Hernandez, J.D., Baum, L.G. Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology 2002, 12, 127R–136R.
8. Fuster, M.M., Esko, J.D. The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5, 526–542.
9. Heusschen, R., Griffioen, A.W., Thijssen, V.L. Galectin-9 in tumor biology: A jack of multiple trades. Biochim. Biophys. Acta 2013, 1836, 177–185.
10. Vladoiu, M.C., Labrie, M., St-Pierre, Y. Intracellular galectins in cancer cells: Potential new targets for therapy (Review). Int. J. Oncol. 2014, 44, 1001–1014.
11. Türeci, O., Schmitt, H., Fadle, N., Pfreundschuh, M., Sahin, U. Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J. Biol. Chem. 1997, 272, 6416–6422.
12. Wada, J., Kanwar, Y.S. Identification and characterization of galectin-9, a novel _-galactoside-binding mammalian lectin. J. Biol. Chem. 1997, 272, 6078–6086.
13. Leal-Pinto, E., Tao, W., Rappaport, J., Richardson, M., Knorr, B.A., Abramson, R.G. Molecular cloning and functional reconstitution of a urate transporter/channel. J. Biol. Chem. 1997, 272, 617–625.
14. Matsumoto, R., Matsumoto, H., Seki, M., Hata, M., Asano, Y., Kanegasaki, S., Stevens, R.L., Hirashima, M. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J. Biol. Chem. 1998, 273, 16976–16984.
15. Kuroda, J., Yamamoto, M., Nagoshi, H., Kobayashi, T., Sasaki, N., Shimura, Y., Horiike, S., Kimura, S., Yamauchi, A., Hirashima, M., et al. Targeting activating transcription factor 3 by galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol. Cancer Res. 2010, 8, 994–1001.
16. Kobayashi, T., Kuroda, J., Ashihara, E., Oomizu, S., Terui, Y., Taniyama, A., Adachi, S., Takagi, T., Yamamoto, M., Sasaki, N., et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia 2010, 24, 843–850.
17. Majno, G., Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol. 1995, 146, 3–15.
18. Galluzzi, L., Vitale, I., Abrams, J.M., Alnemri, E.S., Baehrecke, E.H., Blagosklonny, M.V., Dawson, T.M., Dawson, V.L., El-Deiry, W.S., Fulda, S., et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 2012, 19, 107–120.
19. McLuskey, K., Mottram, J.C. Comparative structural analysis of the caspase family with other clan CD cysteine peptidases. Biochem. J. 2015, 466, 219–232.
20. Delbridge, A.R., Strasser, A. The Bcl-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015, 22, 1071–1080.
21. Adams, J.M., Cory, S. Bcl-2-regulated apoptosis: Mechanism and therapeutic potential. Curr. Opin. Immunol. 2007, 19, 488–496.
22. Willis, S.N., Adams, J.M. Life in the balance: how BH3-only proteins induce apoptosis. Curr. Opin. Cell Biol. 2005, 17, 617–625.
23. Guicciardi, M.E., Gores, G.J. Life and death by death receptors. FASEB J. 2009, 23, 1625–1637.
24. Boatright, K.M., Salvesen, G.S. Mechanisms of caspase activation. Curr. Opin. Cell Biol. 2003, 15, 725–731.
25. Green, D.R., Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626–629.
26. Danial, N.N., Korsmeyer, S.J. Cell death: Critical control points. Cell 2004, 116, 205–219.
27. Degterev, A., Boyce, M., Yuan, J. A decade of caspases. Oncogene 2003, 22, 8543–8567.
28. Hanahan, D., Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
29. Lowe, S.W., Cepero, E., Evan, G. Intrinsic tumour suppression. Nature 2004, 432, 307–315.
30. Helenius, A., Aebi, M. Intracellular functions of N-linked glycans. Science 2001, 291, 2364–2369.
31. Nairn, A.V., York, W.S., Harris, K., Hall, E.M., Pierce, J.M., Moremen, K.W. Regulation of glycan structures in animal tissues: Transcript profiling of glycan-related genes. J. Biol. Chem. 2008, 283, 17298–17313.
32. Lauc, G., Pezer, M., Rudan, I., Campbell, H. Mechanisms of disease: the human N-glycome. Biochim. Biophys. Acta 2016, 1860, 1574–1582.
33. Chia, J., Goh, G., Bard, F. Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives. Biochim. Biophys. Acta 2016, 1860, 1623–1639.
34. Gupta, G., Surolia, A., Sampathkumar, S.G. Lectin microarrays for glycomic analysis. OMICS 2010, 14, 419–436.
35. Shatnyeva, O.M., Kubarenko, A.V., Weber, C.E., Pappa, A., Schwartz-Albiez, R., Weber, A.N., Krammer, P.H., Lavrik, I.N. Modulation of the CD95-induced apoptosis: The role of CD95 N-glycosylation. PLoS ONE 2011, 6, e19927.
36. Charlier, E., Condé, C., Zhang, J., Deneubourg, L., di Valentin, E., Rahmouni, S., Chariot, A., Agostinis, P., Pang, P.C., Haslam, S.M., et al. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity. Leukemia 2010, 24, 821–832.
37. Moriwaki, K., Noda, K., Furukawa, Y., Ohshima, K., Uchiyama, A., Nakagawa, T., Taniguchi, N., Daigo, Y., Nakamura, Y., Hayashi, N., et al. Deficiency of GMDS leads to escape from NK cell-mediated tumor surveillance through modulation of TRAIL signaling. Gastroenterology 2009, 137, 188–198.
38. Moriwaki, K., Shinzaki, S., Miyoshi, E. GDP-mannose-4, 6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J. Biol. Chem. 2011, 286, 43123–43133.
39. Lichtenstein, R.G., Rabinovich, G.A. Glycobiology of cell death: When glycans and lectins govern cell fate. Cell Death Differ. 2013, 20, 976–986.
40. Matarrese, P., Tinari, A., Mormone, E., Bianco, G.A., Toscano, M.A., Ascione, B., Rabinovich, G.A., Malorni, W. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J. Biol. Chem. 2005, 280, 6969–6985.
41. Fukumori, T., Takenaka, Y., Oka, N., Yoshii, T., Hogan, V., Inohara, H., Kanayama, H.O., Kim, H.R., Raz, A. Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res. 2004, 64, 3376–3379.
42. Mazurek, N., Byrd, J.C., Sun, Y., Hafley, M., Ramirez, K., Burks, J., Bresalier, R.S. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ. 2012, 19, 523–533.
43. Brewer, C.F., Miceli, M.C., Baum, L.G. Clusters, bundles, arrays and lattices: Novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr. Opin. Struct. Biol. 2002, 12, 616–623.
44. Bacigalupo, M.L., Manzi, M., Rabinovich, G.A., Troncoso, M.F. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J. Gastroenterol. 2013, 19, 8831–8849.
45. Hirashima, M., Ueno, M., Kamiya, K., Higuchi, S., Matsumoto, R. Functional heterogeneity of human eosinophil chemotactic lymphokines. Lymphokine Cytokine Res. 1991, 10, 481–486.
46. Hirashima, M., Ueno, M., Higuchi, S., Matsumoto, T., Sakata, K.M., Matsumoto, R., Adachi, M. Establishment of a human T-cell line constitutively producing several eosinophil chemotactic lymphokines and their functional heterogeneity on eosinophils. Lymphokine Cytokine Res. 1992, 11, 331–338.
47. Matsushita, N., Nishi, N., Seki, M., Matsumoto, R., Kuwabara, I., Liu, F.T., Hata, Y., Nakamura, T., Hirashima, M. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J. Biol. Chem. 2000, 275, 8355–8360.
48. Lipkowitz, M.S., Leal-Pinto, E., Rappoport, J.Z., Najfeld, V., Abramson, R.G. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J. Clin. Investig. 2001, 107, 1103–1115.
49. Nagae, M., Nishi, N., Murata, T., Usui, T., Nakamura, T., Wakatsuki, S., Kato, R. Crystal structure of the galectin-9 N-terminal carbohydrate recognition domain from Mus musculus reveals the basic mechanism of carbohydrate recognition. J. Biol. Chem. 2006, 281, 35884–35893.
50. Yoshida, H., Teraoka, M., Nishi, N., Nakakita, S., Nakamura, T., Hirashima, M., Kamitori, S. X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J. Biol. Chem. 2010, 285, 36969–36976.
51. Bi, S., Earl, L.A., Jacobs, L., Baum, L.G. Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. J. Biol. Chem. 2008, 283, 12248–12258.
52. Li, Y., Feng, J., Geng, S., Geng, S., Wei, H., Chen, G., Li, X., Wang, L., Wang, R., Peng, H., et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol. Immunol. 2011, 48, 670–677.
53. Nishi, N., Itoh, A., Fujiyama, A., Yoshida, N., Araya, S., Hirashima, M., Shoji, H., Nakamura, T. Development of highly stable galectins: Truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett. 2005, 579, 2058–2064.
54. Sato, M., Nishi, N., Shoji, H., Seki, M., Hashidate, T., Hirabayashi, J., Kasai Ki, K., Hata, Y., Suzuki, S., Hirashima, M., et al. Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology 2002, 12, 191–197.
55. Matsumoto, R., Hirashima, M., Kita, H., Gleich, G.J. Biological activities of ecalectin: A novel eosinophil-activating factor. J. Immunol. 2002, 168, 1961–1967.
56. Earl, L.A., Bi, S., Baum, L.G. Galectin multimerization and lattice formation are regulated by linker region structure. Glycobiology 2011, 21, 6–12.
57. Lahm, H., Hoeflich, A., Andre, S., Sordat, B., Kaltner, H., Wolf, E., Gabius, H.J. Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain. Int. J. Oncol. 2000, 17, 519–524.
58. Heusschen, R., Freitag, N., Tirado-González, I., Barrientos, G., Moschansky, P., Muñoz-Fernández, R., Leno-Durán, E., Klapp, B.F., Thijssen, V.L., Blois, S.M. Profiling Lgals9 splice variant expression at the fetal-maternal interface: Implications in normal and pathological human pregnancy. Biol. Reprod. 2013, 88, 22.
59. Hirashima, M., Kashio, Y., Nishi, N., Yamauchi, A., Imaizumi, T.A., Kageshita, T., Saita, N., Nakamura, T. Galectin-9 in physiological and pathological conditions. Glycoconj. J. 2004, 19, 593–600.
60. Chabot, S., Kashio, Y., Seki, M., Shirato, Y., Nakamura, K., Nishi, N., Nakamura, T., Matsumoto, R., Hirashima, M. Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology 2002, 12, 111–118.
61. Oomizu, S., Arikawa, T., Niki, T., Kadowaki, T., Ueno, M., Nishi, N., Yamauchi, A., Hattori, T., Masaki, T., Hirashima, M. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS ONE 2012, 7, e48574.
62. Keryer-Bibens, C., Pioche-Durieu, C., Villemant, C., Souquère, S., Nishi, N., Hirashima, M., Middeldorp, J., Busson, P. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral latent membrane protein 1 and the immunomodulatory protein galectin 9. BMC Cancer 2006, 6, 283.
63. Mrizak, D., Martin, N., Barjon, C., Jimenez-Pailhes, A.S., Mustapha, R., Niki, T., Guigay, J., Pancré, V., de Launoit, Y., Busson, P., et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J. Natl Cancer Inst. 2015, 107, 363.
64. Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M., Urashima, T., Oka, T., Futai, M., Muller, W.E., et al. Oligosaccharide specificity of galectins: A search by frontal affinity chromatography. Biochim. Biophys. Acta 2002, 1572, 232–254.
65. Sacchettini, J.C., Baum, L.G., Brewer, C.F. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. Biochemistry 2001, 40, 3009–3015.
66. Collins, B.E., Paulson, J.C. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. Curr. Opin. Chem. Biol. 2004, 8, 617–625.
67. Garner, O.B., Baum, L.G. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. Biochem. Soc. Trans. 2008, 36, 1472–1477.
68. Pace, K.E., Lee, C., Stewart, P.L., Baum, L.G. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J. Immunol. 1999, 163, 3801–3811.
69. Belardi, B., O’Donoghue, G.P., Smith, A.W., Groves, J.T., Bertozzi, C.R. Investigating cell surface galectin-mediated cross-linking on glycoengineered cells. J. Am. Chem. Soc. 2012, 134, 9549–9552.
70. Wada, J., Ota, K., Kumar, A., Wallner, E.I., Kanwar, Y.S. Developmental regulation, expression, and apoptotic potential of galectin-9, a _-galactoside binding lectin. J. Clin. Investig. 1997, 99, 2452–2461.
71. Tsuboi, Y., Abe, H., Nakagawa, R., Oomizu, S., Watanabe, K., Nishi, N., Nakamura, T., Yamauchi, A., Hirashima, M. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin. Immunol. 2007, 124, 221–233.
72. Spitzenberger, F., Graessler, J., Schroeder, H.E. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. Biochimie 2001, 83, 851–862.
73. Thijssen, V.L., Hulsmans, S., Griffioen, A.W. The galectin profile of the endothelium: Altered expression and localization in activated and tumor endothelial cells. Am. J. Pathol. 2008, 172, 545–553.
74. Asakura, H., Kashio, Y., Nakamura, K., Seki, M., Dai, S., Shirato, Y., Abedin, M.J., Yoshida, N., Nishi, N., Imaizumi, T., et al. Selective eosinophil adhesion to fibroblast via IFN--induced galectin-9. J. Immunol. 2002, 169, 5912–5918.
75. Zhang, Z.Y., Dong, J.H., Chen, Y.W., Wang, X.Q., Li, C.H., Wang, J., Wang, G.Q., Li, H.L., Wang, X.D. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. Asian Pac. J. Cancer Prev. 2012, 13, 2503–2509.
76. Laderach, D.J., Gentilini, L.D., Giribaldi, L., Delgado, V.C., Nugnes, L., Croci, D.O., Al Nakouzi, N., Sacca, P., Casas, G., Mazza, O., et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013, 73, 86–96.
77. Mayoral, M.A., Mayoral, C., Meneses, A., Villalvazo, L., Guzman, A., Espinosa, B., Ochoa, J.L., Zenteno, E., Guevara, J. Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Investig. 2008, 26, 615–623.
78. Cada, Z., Smetana, K., Lacina, L., Plzáková, Z., Stork, J., Kaltner, H., Russwurm, R., Lensch, M., André, S., Gabius, H.J. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. Folia Biol. (Praha) 2009, 55, 145–152.
79. Kageshita, T., Kashio, Y., Yamauchi, A., Seki, M., Abedin, M.J., Nishi, N., Shoji, H., Nakamura, T., Ono, T., Hirashima, M. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int. J. Cancer 2002, 99, 809–816.
80. Chan, S.W., Kallarakkal, T.G., Abraham, M.T. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. Asian Pac. J. Cancer Prev. 2014, 15, 2145–2152.
81. Terris, B., Blaveri, E., Crnogorac-Jurcevic, T., Jones, M., Missiaglia, E., Ruszniewski, P., Sauvanet, A., Lemoine, N.R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 2002, 160, 1745–1754.
82. Yang, J., Zhu, L., Cai, Y., Suo, J., Jin, J. Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. Int. J. Oncol. 2014, 45, 1313–1320.
83. Jiang, J., Jin, M.S., Kong, F., Cao, D., Ma, H.X., Jia, Z., Wang, Y.P., Suo, J., Cao, X. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS ONE 2013, 8, e81799.
84. Kashio, Y., Nakamura, K., Abedin, M.J., Seki, M., Nishi, N., Yoshida, N., Nakamura, T., Hirashima, M. Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J. Immunol. 2003, 170, 3631–3636.
85. Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., Strom, T.B., Kuchroo, V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6, 1245–1252.
86. Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E.A., Coyle, A.J., Sobel, R.A., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415, 536–541.
87. Miao, E.A., Leaf, I.A., Treuting, P.M., Mao, D.P., Dors, M., Sarkar, A., Warren, S.E., Wewers, M.D., Aderem, A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 2010, 11, 1136–1142.
88. Vande Walle, L., Lamkanfi, M. Pyroptosis. Curr. Biol. 2016, 26, R568–R572.
89. Cookson, B.T., Brennan, M.A. Pro-inflammatory programmed cell death. Trends Microbiol. 2001, 9, 113–114.
90. Edgeworth, J.D., Spencer, J., Phalipon, A., Griffin, G.E., Sansonetti, P.J. Cytotoxicity and interleukin-1β processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur. J. Immunol. 2002, 32, 1464–1471.
91. Fink, S.L., Bergsbaken, T., Cookson, B.T. Anthrax lethal toxin and salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc. Natl Acad. Sci. USA 2008, 105, 4312–4317.
92. Cuesta, N., Nhu, Q.M., Zudaire, E., Polumuri, S., Cuttitta, F., Vogel, S.N. IFN regulatory factor-2 regulates macrophage apoptosis through a STAT1/3- and caspase-1-dependent mechanism. J. Immunol. 2007, 178, 3602–3611.
93. Sollberger, G., Strittmatter, G.E., Grossi, S., Garstkiewicz, M., Auf dem Keller, U., French, L.E., Beer, H.D. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. J. Investig. Dermatol. 2015, 135, 1395–1404.
94. Wiersma, V.R., de Bruyn, M., van Ginkel, R.J., Sigar, E., Hirashima, M., Niki, T., Nishi, N., Samplonius, D.F., Helfrich, W., Bremer, E. The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J. Investig. Dermatol. 2012, 132, 2302–2305.
95. Fujita, K., Iwama, H., Sakamoto, T., Okura, R., Kobayashi, K., Takano, J., Katsura, A., Tatsuta, M., Maeda, E., Mimura, S., et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Int. J. Oncol. 2015, 46, 2419–2430.
96. Kobayashi, K., Morishita, A., Iwama, H., Fujita, K., Okura, R., Fujihara, S., Yamashita, T., Fujimori, T., Kato, K., Kamada, H., et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol. Rep. 2015, 34, 1761–1770.
97. Tadokoro, T., Morishita, A., Fujihara, S., Iwama, H., Niki, T., Fujita, K., Akashi, E., Mimura, S., Oura, K., Sakamoto, T., et al. Galectin-9: An anticancer molecule for gallbladder carcinoma. Int. J. Oncol. 2016, 48, 1165–1174.
98. Takano, J., Morishita, A., Fujihara, S., Iwama, H., Kokado, F., Fujikawa, K., Fujita, K., Chiyo, T., Tadokoro, T., Sakamoto, T., et al. Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. Oncol. Rep. 2016, 35, 851–860.
99. Fujihara, S., Mori, H., Kobara, H., Rafiq, K., Niki, T., Hirashima, M., Masaki, T. Galectin-9 in cancer therapy. Recent Pat. Endocr. Metab. Immune Drug Discov. 2013, 7, 130–137.
100. Seki, M., Oomizu, S., Sakata, K.M., Sakata, A., Arikawa, T., Watanabe, K., Ito, K., Takeshita, K., Niki, T., Saita, N., et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127, 78–88.
101. Mengshol, J.A., Golden-Mason, L., Arikawa, T., Smith, M., Niki, T., McWilliams, R., Randall, J.A., McMahan, R., Zimmerman, M.A., Rangachari, M., et al. A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS ONE 2010, 5, e9504.
102. Irie, A., Yamauchi, A., Kontani, K., Kihara, M., Liu, D., Shirato, Y., Seki, M., Nishi, N., Nakamura, T., Yokomise, H., et al. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin. Cancer Res. 2005, 11, 2962–2968.
103. Seki, M., Sakata, K.M., Oomizu, S., Arikawa, T., Sakata, A., Ueno, M., Nobumoto, A., Niki, T., Saita, N., Ito, K., et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum. 2007, 56, 3968–3976.
104. Chagan-Yasutan, H., Saitoh, H., Ashino, Y., Arikawa, T., Hirashima, M., Li, S., Usuzawa, M., Oguma, S., O Telan, E.F., Obi, C.L., et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. Tohoku J. Exp. Med. 2009, 218, 285–292.